Bafna Pharmaceuticals Limited (BAFNAPH) — Capital Reinvestment Ratio

Latest as of September 2025: 1.76x

Bafna Pharmaceuticals Limited (BAFNAPH) has a Capital Reinvestment Ratio of 1.76x as of September 2025, meaning it reinvests 2% of its operating cash flow (Rs93.12 Million) in capital expenditures (Rs164.17 Million). See Bafna Pharmaceuticals Limited free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

1.76x
Capex / Operating Cash Flow

Operating Cash Flow

Rs93.12 Million
INR

Capital Expenditures

Rs164.17 Million
INR

Data as of

Sep 2025
Most recent filing

Bafna Pharmaceuticals Limited Capital Reinvestment Ratio (2007–2026)

This chart tracks Bafna Pharmaceuticals Limited's Capital Reinvestment Ratio across 10 annual periods.

Annual Capital Reinvestment Ratio for Bafna Pharmaceuticals Limited (2007–2026)

Year-by-year Capital Reinvestment Ratio for Bafna Pharmaceuticals Limited from 2007 to 2026. For live market cap and broader valuation context, see BAFNAPH market cap overview.

Year Reinvestment Ratio Operating CF (INR) Capital Expenditures YoY Change
2026 2.11x Rs118.27 Million Rs249.03 Million ▲ +88.1%
2025 1.12x Rs195.29 Million Rs218.60 Million ▼ -31.8%
2024 1.64x Rs94.85 Million Rs155.78 Million ▼ -1.0%
2023 1.66x Rs49.52 Million Rs82.19 Million ▲ +114.1%
2022 0.78x Rs97.28 Million Rs75.41 Million ▼ -69.4%
2016 2.53x Rs9.11 Million Rs23.07 Million ▲ +246.7%
2015 0.73x Rs106.65 Million Rs77.90 Million ▼ -33.1%
2014 1.09x Rs16.06 Million Rs17.53 Million ▲ +1778.7%
2013 0.06x Rs366.32 Million Rs21.28 Million ▼ -96.9%
2007 1.85x Rs101.06 Million Rs187.01 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow